Compare TG Therapeutics Inc (TGTX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Microelectronics Corp — how do they compare? TG Therapeutics Inc trades at $54.95 (market cap $8.16B), while United Microelectronics Corp trades at $22.98 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 7.1× TG Therapeutics Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and United Microelectronics Corp for 42 Days on average.
| TGTX | UMC | |
|---|---|---|
Market Cap | $8.16B | $58.02B |
Volume | 1,735,121 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $59.06 | $28.02 |
52-Week Low | $26.94 | $7.02 |
Typical Hold Time | 16 Days | 42 Days |
Enterprise Value | $8.37B | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
UMC trades at $22.92, down 1.67% on the day, with a bullish technical signal despite recent weakness. The company has delivered strong earnings beats in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue is projected to grow to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow trends show a positive turnaround with 2025 net cash flow of $5.66 billion after two years of negative flows.
The outlook remains positive with strong profitability metrics and analyst upgrades, though competition and market volatility present risks. The stock appears fundamentally sound with improving cash generation and earnings momentum, supported by AI-driven semiconductor demand. Valuation metrics suggest reasonable pricing relative to growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
